EUVIMEDOpdag EUVIMED
Open access

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors

Seyed Arad Moghadasi iD, Emmanuel Heilmann iD, Ahmed Magdy Khalil iD, Christina Nnabuife iD, Fiona L Kearns iD, Chengjin Ye iD, Sofia N Moraes iD, Francesco Costacurta iD, Morgan A Esler iD, Hideki Aihara iD, Dorothee von Laer iD, Luis Martinez-Sobrido iD and 3 more

Science Advances · 2023

DOI: 10.1126/sciadv.ade8778 ↗

At a glance

Journal article in Science Advances, 2023. Written by Seyed Arad Moghadasi and 14 co-authors. Institution: Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Twin Cities, Minneapolis, MN 55455, USA. Major MEDLINE topics: SARS-CoV-2, COVID-19. Cited 165 times so far (Crossref); 57 references. The full text is freely available in PubMed Central. Funded by: NIGMS NIH HHS, NIAID NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Vaccines and drugs have helped reduce disease severity and blunt the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, ongoing virus transmission, continuous evolution, and increasing selective pressures have the potential to yield viral variants capable of resisting these interventions. Here, we investigate the susceptibility of natural variants of the main protease [M pro ; 3C-like protease (3CL pro )] of SARS-CoV-2 to protease inhibitors. Multiple single amino acid changes in M pro confer resistance to nirmatrelvir (the active component of Paxlovid). An additional clinical-stage inhibitor, ensitrelvir (Xocova), shows a different resistance mutation profile. Importantly, phylogenetic analyses indicate that several of these resistant variants have pre-existed the introduction of these drugs into the human population and are capable of spreading. These results encourage the monitoring of resistance variants and the development of additional protease inhibitors and other antiviral drugs with different mechanisms of action and resistance profiles for combinatorial therapy.

Subjects

MeSH terms (MEDLINE)

SARS-CoV-2COVID-19HumansProtease InhibitorsPhylogenyPeptide HydrolasesDrug CombinationsLactamsLeucineNitrilesProlineRitonavirIndazolesTriazinesTriazoles

Substances

Protease InhibitorsPeptide Hydrolasesnirmatrelvir and ritonavir drug combinationDrug CombinationsLactamsLeucineNitrilesProlineRitonavirensitrelvir

Authors and institutions

  • Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Twin Cities, Minneapolis, MN 55455, USA.
  • Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
  • Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
  • Department of Zoonotic Diseases, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt.
  • Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093, USA.

ORCID profiles: Seyed Arad Moghadasi, Emmanuel Heilmann, Ahmed Magdy Khalil, Christina Nnabuife, Fiona L Kearns, Chengjin Ye, Sofia N Moraes, Francesco Costacurta, Morgan A Esler, Hideki Aihara, Dorothee von Laer, Luis Martinez-Sobrido, Timothy Palzkill, Rommie E Amaro, Reuben S Harris

Funding

  • NIGMS NIH HHS
  • NIAID NIH HHS

Cite

APA

Moghadasi, S. A., Heilmann, E., Khalil, A. M., Nnabuife, C., Kearns, F. L., Ye, C., Moraes, S. N., Costacurta, F., Esler, M. A., Aihara, H., von Laer, D., Martinez-Sobrido, L., Palzkill, T., Amaro, R. E., & Harris, R. S. (2023). Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. Science Advances. https://doi.org/10.1126/sciadv.ade8778

Vancouver

Moghadasi SA, Heilmann E, Khalil AM, Nnabuife C, Kearns FL, Ye C, et al. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. Science Advances. 2023. doi:10.1126/sciadv.ade8778

BibTeX
@article{Moghadasi2023,
  author = {Moghadasi, Seyed Arad and Heilmann, Emmanuel and Khalil, Ahmed Magdy and Nnabuife, Christina and Kearns, Fiona L and Ye, Chengjin and Moraes, Sofia N and Costacurta, Francesco and Esler, Morgan A and Aihara, Hideki and von Laer, Dorothee and Martinez-Sobrido, Luis and Palzkill, Timothy and Amaro, Rommie E and Harris, Reuben S},
  title = {Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors},
  journal = {Science Advances},
  year = {2023},
  doi = {10.1126/sciadv.ade8778}
}
Start for free →